Anti-Cav3.1 Ca2+ channel [N178A/9R-2b]
(Plasmid
#206660)
-
PurposeMammalian Expression Plasmid of anti-Cav3.1 Ca2+ channel (Mouse). Derived from hybridoma N178A/9-2b.
-
Depositing Lab
-
Sequence Information
-
Sequences (3) — Accept Affinity Reagent Sequence Policy
-
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 206660 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneP1316-IgG2b
-
Backbone manufacturerGavin Wright, Sanger; Yves Durocher, NRCC
- Backbone size w/o insert (bp) 5925
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameanti-Cav3.1 Ca2+ channel (Mus musculus) recombinant Mouse monoclonal antibody
-
Alt nameQ9WUT2
-
SpeciesM. musculus (mouse)
-
Entrez GeneCacna1g (a.k.a. Cav3.1d, [a]1G, a1G, alpha-1G, mKIAA1123)
- Promoter Dual CMV
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NotI (unknown if destroyed)
- 3′ cloning site BssHII (unknown if destroyed)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This is a recombinant antibody derived from RRID: AB_2941231. Isotype: IgG2a. A portion of this plasmid was derived from a plasmid, pTT3, which was obtained from Yves Durocher, National Research Council of Canada- Biotechnology Research Institute
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Anti-Cav3.1 Ca2+ channel [N178A/9R-2b] was a gift from James Trimmer (Addgene plasmid # 206660 ; http://n2t.net/addgene:206660 ; RRID:Addgene_206660) -
For your References section:
High-volume hybridoma sequencing on the NeuroMabSeq platform enables efficient generation of recombinant monoclonal antibodies and scFvs for neuroscience research. Mitchell KG, Gong B, Hunter SS, Burkart-Waco D, Gavira-O'Neill CE, Templeton KM, Goethel ME, Bzymek M, MacNiven LM, Murray KD, Settles ML, Froenicke L, Trimmer JS. Sci Rep. 2023 Sep 27;13(1):16200. doi: 10.1038/s41598-023-43233-4. 10.1038/s41598-023-43233-4 PubMed 37758930